Shanghai Junshi Biosciences (SHA:688180, HKG:1877) achieved the primary endpoints of a phase 3 trial for its toripalimab advanced liver cancer treatment, according to a Wednesday filing with the Shanghai Stock Exchange.
The drug showed progression-free survival and overall survival during the trial, the filing said.
Junshi Bio will submit a marketing application for the drug soon, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments